SCHEMBL23043

SCHEMBL23043

COc1cc(C=O)ccc1C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.70
TSHR P16473 1/20 0.70
HPGD P15428 2/20 0.63
TRIM24 O15164 1/20 0.63
ALDH5A1 P51649 1/20 0.63
ABAT P80404 1/20 0.63
TDP1 Q9NUW8 1/20 0.63
TRIM33 Q9UPN9 1/20 0.63
FDPS P14324 1/20 0.59
AOX1 Q06278 1/20 0.58
TTR P02766 1/20 0.54
ALDH1A3 P47895 1/20 0.53
TUBB1 Q9H4B7 1/20 0.49
CYP2A6 P11509 1/20 0.48
MAPT P10636 5/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
HTT P42858 2/20 0.47
LMNA P02545 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KDM4E B2RXH2 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29956457 1.00 ALDH1A1 (0.70) ALDH1A1TSHRHPGDTRIM24ALDH5A1
SCHEMBL493442 0.83 ALDH1A1 (0.70) ALDH1A1TSHRHPGDTRIM24ALDH5A1
3,4-Dimethoxybenzaldehyde SCHEMBL25202 0.83 ALDH1A1 (1.00) ALDH1A1TSHRHPGDTRIM24ALDH5A1
3,4-Dimethoxybenzaldehyde SCHEMBL5308959 0.83 ALDH1A1 (1.00) ALDH1A1TSHRHPGDTRIM24ALDH5A1
3,4-Dimethoxybenzaldehyde SCHEMBL29364994 0.83 ALDH1A1 (1.00) ALDH1A1TSHRHPGDTRIM24ALDH5A1
3,4-Dimethoxybenzaldehyde SCHEMBL1330962 0.83 ALDH1A1 (1.00) ALDH1A1TSHRHPGDTRIM24ALDH5A1
SCHEMBL30882827 0.81 ALDH1A1 (0.73) ALDH1A1TSHRHPGDTRIM24ALDH5A1
3,4-Dimethoxybenzaldehyde SCHEMBL29624454 0.81 ALDH1A1 (0.96) ALDH1A1TSHRHPGDTRIM24ALDH5A1
3,4-Dimethoxybenzaldehyde SCHEMBL28205798 0.81 ALDH1A1 (0.96) ALDH1A1TSHRHPGDTRIM24ALDH5A1
SCHEMBL18873942 0.79 ALDH1A1 (0.64) ALDH1A1TSHRHPGDTRIM24ALDH5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109487309-B Novel cyanide-free bright alkaline copper plating complexing agent 武汉奥克特种化学有限公司 2021-03-23 CN claimed
JP-4587669-B2 2010-11-24 JP claimed
JP-2005509662-A 2005-04-14 JP claimed
EP-1443915-A1 PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING OXY GROUP-BEARING AROMATIC ALDEHYDES Cutanix Corporation (US) 2004-08-11 EP claimed
US-20030124157-A1 Compositions containing aromatic aldehydes and their use in treatments ALLERGAN, INC. 2003-07-03 US claimed
WO-2003043621-A1 PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING OXY GROUP-BEARING AROMATIC ALDEHYDES CUTANIX CORPORATION (US) 2003-05-30 WO claimed
EP-0075629-A1 Imidazole derivatives, their preparation, and their pharmaceutical compositions Sumitomo Chemical Industries Ltd. (JP) 1983-04-06 EP claimed
CN-122036668-A Alpha, beta unsaturated ketone substituted chromone derivative and medicinal use thereof 中国药科大学 2026-05-15 CN disclosed
CN-119371391-A Aroyl compound and preparation method and application thereof 河北医科大学 2025-01-28 CN disclosed
US-20240400562-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LHOTSE BIO, INC. 2024-12-05 US disclosed
WO-2024183807-A1 ARYL FUSED IMIDAZOLE COMPOUND AND MEDICAL USE THEREOF 哈尔滨三联药业股份有限公司 2024-09-12 WO disclosed
CN-118619885-A Arylimidazole compound and medical application thereof 哈尔滨三联药业股份有限公司 2024-09-10 CN disclosed
EP-4419509-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY Lhotse Bio, Inc. (US) 2024-08-28 EP disclosed
US-6251910-B1 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists ASTRAZENECA UK LIMITED (GB) 2001-06-26 US disclosed
EP-0996621-A1 NOVEL COMPOUNDS Astra Pharmaceuticals Limited (GB) 2000-05-03 EP disclosed
WO-1999005143-A1 NOVEL COMPOUNDS ASTRA PHARMACEUTICALS LTD. (GB) 1999-02-04 WO disclosed
EP-0083228-B1 PHARMACEUTICALLY ACTIVE PHENYLCARBOXYLIC ACID DERIVATIVES ICI AMERICAS INC. (US) 1985-05-15 EP disclosed
US-4499299-A Pharmaceutically active phenylcarboxylic acid derivatives ICI AMERICAS INC. (US) 1985-02-12 US disclosed
US-4444567-A ALKOXY BENZALDEHYDES, ALKOXY BENZOATES PHILLIPS PETROLEUM COMPANY (US) 1984-04-24 US disclosed
EP-0083228-A1 Pharmaceutically active phenylcarboxylic acid derivatives ICI AMERICAS INC. (US) 1983-07-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400562-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY LPAR1, LPAR2, LPAR6 ALDH1A1 1774/4885TSHR 1266/4885HPGD 1540/4885
US-20030124157-A1 Compositions containing aromatic aldehydes and their use in treatments TYR, ALDH2, AOX1 ALDH1A1 4/4885TSHR 4387/4885HPGD 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.